Renate Ruth van Den Bos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Renate Ruth van Den Bos has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Tamar Nijsten
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
9 shared publications T. Nijsten
Department of Dermatology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam the Netherlands
5 shared publications- Antien L. Mooyaart
Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications - Eveline R. Y. Scheerders
Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands
4 shared publications - Marlies Wakkee
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center , Rotterdam
4 shared publications - Judith Zoutendijk
Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center , Rotterdam
3 shared publications
Latest Publications
- 10 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Five-year recurrence rate of cutaneous squamous cell carcinoma after Mohs micrographic surgery versus standard excision: a prospective multicentre cohort study
Background: Mohs micrographic surgery (MMS) is a tissue-sparing alternative to standard excision (SE) for treatment of cutaneous squamous cell carcinoma (CSCC). Prospective studies comparing recurrence risk between MMS and SE remain limited, and no randomized controlled trials exist. In clinical practice, MMS tends to be selectively offered for higher-risk tumours in cosmetically sensitive areas. Objectives: To compare 5-year recurrence rates between MMS and SE for primary CSCC, and to compare metastasis rates and the ratio of final defect size to initial tumour size. Methods: This was a prospective multicentre cohort study of patients with primary CSCCs treated with MMS or SE in the Netherlands. To detect all recurrences, patients were linked to the Dutch Nationwide Pathology Databank. The Fine and Gray competing risk regression model was used to assess the subdistribution hazard ratio (sHR) for recurrence. Results: A total of 761 patients with 903 completely excised primary CSCCs were included: 629 treated with SE and 274 with MMS. Tumours treated with MMS were more often classified as high stage according to the American Joint Committee on Cancer, eighth edition (AJCC 8) [≥ T2, 55.5% (n = 152/274) vs. 25.3% (n = 159/629); P < 0.001], and more frequently located in the H-zone [76.6% (n = 210/274) vs. 37.0% (n = 233/629), P < 0.001]. The 5-year cumulative incidence of recurrence was 1.7% (95% CI 0.9–3.0%) for SE and 3.3% (95% CI 1.6–5.9%) for MMS. After adjustment for AJCC 8 stage, the sHR for recurrence after MMS compared with SE was 1.51 (95% CI 0.66–3.44; P = 0.33). The 5-year cumulative incidence of metastasis was 0.8% (95% CI 0.3–1.8%) for SE and 1.1% (0.3–3.0%) for MMS. The ratio of final defect size to initial tumour size was smaller for MMS (1.2 vs. 3.0, P < 0.001). Conclusions: No significant difference was found in 5-year recurrence rate between MMS and SE; however, definitive conclusions cannot be drawn about whether a true difference in efficacy exists. MMS resulted in smaller defects, supporting its use in cosmetically or functionally sensitive areas where tissue preservation is important.
- 10 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Five-year recurrence rate of cutaneous squamous cell carcinoma after Mohs micrographic surgery versus standard excision: a prospective multicentre cohort study
Background: Mohs micrographic surgery (MMS) is a tissue-sparing alternative to standard excision (SE) for treatment of cutaneous squamous cell carcinoma (CSCC). Prospective studies comparing recurrence risk between MMS and SE remain limited, and no randomized controlled trials exist. In clinical practice, MMS tends to be selectively offered for higher-risk tumours in cosmetically sensitive areas. Objectives: To compare 5-year recurrence rates between MMS and SE for primary CSCC, and to compare metastasis rates and the ratio of final defect size to initial tumour size. Methods: This was a prospective multicentre cohort study of patients with primary CSCCs treated with MMS or SE in the Netherlands. To detect all recurrences, patients were linked to the Dutch Nationwide Pathology Databank. The Fine and Gray competing risk regression model was used to assess the subdistribution hazard ratio (sHR) for recurrence. Results: A total of 761 patients with 903 completely excised primary CSCCs were included: 629 treated with SE and 274 with MMS. Tumours treated with MMS were more often classified as high stage according to the American Joint Committee on Cancer, eighth edition (AJCC 8) [≥ T2, 55.5% (n = 152/274) vs. 25.3% (n = 159/629); P < 0.001], and more frequently located in the H-zone [76.6% (n = 210/274) vs. 37.0% (n = 233/629), P < 0.001]. The 5-year cumulative incidence of recurrence was 1.7% (95% CI 0.9–3.0%) for SE and 3.3% (95% CI 1.6–5.9%) for MMS. After adjustment for AJCC 8 stage, the sHR for recurrence after MMS compared with SE was 1.51 (95% CI 0.66–3.44; P = 0.33). The 5-year cumulative incidence of metastasis was 0.8% (95% CI 0.3–1.8%) for SE and 1.1% (0.3–3.0%) for MMS. The ratio of final defect size to initial tumour size was smaller for MMS (1.2 vs. 3.0, P < 0.001). Conclusions: No significant difference was found in 5-year recurrence rate between MMS and SE; however, definitive conclusions cannot be drawn about whether a true difference in efficacy exists. MMS resulted in smaller defects, supporting its use in cosmetically or functionally sensitive areas where tissue preservation is important.
- 6 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (9) , e106-e107
Evaluation of Lentigo Maligna With Additional Immunohistochemical Staining on Frozen Sections With PRAME, Melan-A, and SOX10
Was not provided for this article.
- 6 July 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (9) , e106-e107
Evaluation of Lentigo Maligna With Additional Immunohistochemical Staining on Frozen Sections With PRAME, Melan-A, and SOX10
Was not provided for this article.
- Open Access
- 30 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (1) , 187-195
Anticoagulation Management and Recurrent Thrombosis after Venous Stenting for Deep Vein Thrombosis and Post-thrombotic Syndrome
- 30 January 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (1) , 187-195
Open AccessAnticoagulation Management and Recurrent Thrombosis after Venous Stenting for Deep Vein Thrombosis and Post-thrombotic Syndrome
- Open Access
- 17 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 862-868
A nationwide study of treatment of lentigo maligna and its recurrence rate in the Netherlands
Background: The treatment of lentigo maligna (LM) can be challenging in older patients and in delicate facial areas. Previous studies have shown that LM in 10% of patients is upstaged to LM melanoma (LMM) after surgery. Objectives: To identify, via a nationwide cohort study, the diagnostic modalities and available treatments for LM in the Netherlands, and to investigate the rates of postoperative upstaging to LMM and recurrence post-treatment. Methods: To investigate the modalities used to diagnose LM and the rate of upstaging to LMM after surgery, data from 2020 were retrieved from the Dutch Nationwide Pathology Databank (‘Palga’). To investigate the available treatments for LM, data were retrieved from the Netherlands Cancer Registry between 2013 and 2016. To investigate post-treatment recurrences, all reports of LM from 2013 to 2021 were retrieved from Palga. Results: In 2020, 1422 patients in the Netherlands were diagnosed with primary LM. Diagnoses were made using a punch biopsy in 60.8% of cases (n = 864) and with an excisional biopsy in 37.1% (n = 527). Half of the patients (n = 713; 50.1%) were treated surgically and 14.2% (n = 101/713) were upstaged to LMM/melanoma after surgery. Between 2013 and 2016, wide local excision (WLE) was performed in 79.7% (n = 2860/3587) of cases of histopathologically confirmed primary LM, staged excision was chosen in 1.6% (n = 58), watchful waiting in 1.5% (n = 55) and noninvasive treatments in 4.5% (n = 162). With a median follow-up until death or censoring at 5.7 years, there were 247 (6.9%) recurrences, with a median time to recurrence of 2.4 years. Conclusions: In the Netherlands, patients with LM are most often diagnosed with a punch biopsy and most are treated with WLE, in line with Dutch melanoma guidelines. Using a nationwide database, 14% of histologically proven cases of LM were upstaged to LMM postsurgery. This should be considered when choosing treatment, especially when considering nonsurgical treatments. The significant number of recurrences in patients who received nonsurgical treatment demonstrates the complexity of treating LM and the importance of balancing histological clearance with sometimes disfiguring surgery in the head-and-neck region.
- 17 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 862-868
Open AccessA nationwide study of treatment of lentigo maligna and its recurrence rate in the Netherlands
Background: The treatment of lentigo maligna (LM) can be challenging in older patients and in delicate facial areas. Previous studies have shown that LM in 10% of patients is upstaged to LM melanoma (LMM) after surgery. Objectives: To identify, via a nationwide cohort study, the diagnostic modalities and available treatments for LM in the Netherlands, and to investigate the rates of postoperative upstaging to LMM and recurrence post-treatment. Methods: To investigate the modalities used to diagnose LM and the rate of upstaging to LMM after surgery, data from 2020 were retrieved from the Dutch Nationwide Pathology Databank (‘Palga’). To investigate the available treatments for LM, data were retrieved from the Netherlands Cancer Registry between 2013 and 2016. To investigate post-treatment recurrences, all reports of LM from 2013 to 2021 were retrieved from Palga. Results: In 2020, 1422 patients in the Netherlands were diagnosed with primary LM. Diagnoses were made using a punch biopsy in 60.8% of cases (n = 864) and with an excisional biopsy in 37.1% (n = 527). Half of the patients (n = 713; 50.1%) were treated surgically and 14.2% (n = 101/713) were upstaged to LMM/melanoma after surgery. Between 2013 and 2016, wide local excision (WLE) was performed in 79.7% (n = 2860/3587) of cases of histopathologically confirmed primary LM, staged excision was chosen in 1.6% (n = 58), watchful waiting in 1.5% (n = 55) and noninvasive treatments in 4.5% (n = 162). With a median follow-up until death or censoring at 5.7 years, there were 247 (6.9%) recurrences, with a median time to recurrence of 2.4 years. Conclusions: In the Netherlands, patients with LM are most often diagnosed with a punch biopsy and most are treated with WLE, in line with Dutch melanoma guidelines. Using a nationwide database, 14% of histologically proven cases of LM were upstaged to LMM postsurgery. This should be considered when choosing treatment, especially when considering nonsurgical treatments. The significant number of recurrences in patients who received nonsurgical treatment demonstrates the complexity of treating LM and the importance of balancing histological clearance with sometimes disfiguring surgery in the head-and-neck region.
- Open Access
- 27 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , 387-388
Exploring patients’ views on a more proactive role for allied healthcare professionals in the identification of suspicious skin lesions: a qualitative study
Patients are generally open to allied healthcare professionals having a more proactive advisory role in identifying suspicious skin lesions, provided appropriate safeguards are in place. Key benefits have included the reduction of patient delays and the facilitation of early detection of skin cancer. However, main concerns include the risk of misdiagnosis and the unintentional exclusion of specific (sub)populations, especially men and individuals with limited financial resources.
- 27 October 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (2) , 387-388
Open AccessExploring patients’ views on a more proactive role for allied healthcare professionals in the identification of suspicious skin lesions: a qualitative study
Patients are generally open to allied healthcare professionals having a more proactive advisory role in identifying suspicious skin lesions, provided appropriate safeguards are in place. Key benefits have included the reduction of patient delays and the facilitation of early detection of skin cancer. However, main concerns include the risk of misdiagnosis and the unintentional exclusion of specific (sub)populations, especially men and individuals with limited financial resources.
- Open Access
- 15 August 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , 307-315
Prevalence and Risk Factors of Chronic Venous Disease in a General Population in The Netherlands: Results from the Rotterdam Study
- 15 August 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , 307-315
Open AccessPrevalence and Risk Factors of Chronic Venous Disease in a General Population in The Netherlands: Results from the Rotterdam Study
- Open Access
- 6 May 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 68 (3) , 387-394
Development and External Validation of a Prediction Model for Patients with Varicose Veins Suitable for Isolated Ambulatory Phlebectomy
- 6 May 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 68 (3) , 387-394
Open AccessDevelopment and External Validation of a Prediction Model for Patients with Varicose Veins Suitable for Isolated Ambulatory Phlebectomy
- Open Access
- 21 February 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 733
Author response to: Comment on: A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Dear Editor
- 21 February 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 733
Open AccessAuthor response to: Comment on: A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Dear Editor
- Open Access
- 5 December 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (3) , 333-342
A randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Background: Current treatment of patients with saphenous trunk and tributary incompetence consists of truncal ablation with concomitant, delayed or no treatment of the tributary. However, reflux of the saphenous trunk may be reversible after treatment of the incompetent tributary. The aim of this study was to determine whether single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP), and whether SAP is a cost-effective alternative to TAP. Methods: A multicentre, non-inferiority RCT was conducted in patients with an incompetent great saphenous vein or anterior accessory saphenous vein with one or more incompetent tributaries. Participants were randomized to receive SAP or TAP. After 9 months, additional truncal treatment was considered for SAP patients with remaining symptoms. The primary outcome was VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms (VEINES-QOL/Sym score) after 12 months. Secondary outcomes were, among others, cost-effectiveness, perceived improvement of symptoms, and anatomical success. Results: Some 464 patients received the allocated treatment (SAP 227, TAP 237). VEINES-QOL scores were 52.7 (95 per cent c.i. 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP; VEINES-Sym scores were 53.5 (52.6 to 54.4) and 54.2 (54.0 to 55.6) respectively. Fifty-eight patients (25.6 per cent) in the SAP group received additional truncal ablation. Treatment with SAP was less costly than treatment with TAP. Conclusion: One year after treatment, participants who underwent SAP had non-inferior health-related quality of life compared with those who had TAP. Treatment with SAP was a cost-effective alternative to TAP at 12 months. Registration number: NTR 4821 (www.trialregister.nl).
- 5 December 2022
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (3) , 333-342
Open AccessA randomized clinical trial of isolated ambulatory phlebectomy versus saphenous thermal ablation with concomitant phlebectomy (SAPTAP Trial)
Background: Current treatment of patients with saphenous trunk and tributary incompetence consists of truncal ablation with concomitant, delayed or no treatment of the tributary. However, reflux of the saphenous trunk may be reversible after treatment of the incompetent tributary. The aim of this study was to determine whether single ambulatory phlebectomy with or without delayed endovenous truncal ablation (SAP) is non-inferior to thermal endovenous ablation with concomitant phlebectomy (TAP), and whether SAP is a cost-effective alternative to TAP. Methods: A multicentre, non-inferiority RCT was conducted in patients with an incompetent great saphenous vein or anterior accessory saphenous vein with one or more incompetent tributaries. Participants were randomized to receive SAP or TAP. After 9 months, additional truncal treatment was considered for SAP patients with remaining symptoms. The primary outcome was VEnous INsufficiency Epidemiological and Economic Study Quality of Life/Symptoms (VEINES-QOL/Sym score) after 12 months. Secondary outcomes were, among others, cost-effectiveness, perceived improvement of symptoms, and anatomical success. Results: Some 464 patients received the allocated treatment (SAP 227, TAP 237). VEINES-QOL scores were 52.7 (95 per cent c.i. 51.9 to 53.9) for SAP and 53.8 (53.3 to 55.1) for TAP; VEINES-Sym scores were 53.5 (52.6 to 54.4) and 54.2 (54.0 to 55.6) respectively. Fifty-eight patients (25.6 per cent) in the SAP group received additional truncal ablation. Treatment with SAP was less costly than treatment with TAP. Conclusion: One year after treatment, participants who underwent SAP had non-inferior health-related quality of life compared with those who had TAP. Treatment with SAP was a cost-effective alternative to TAP at 12 months. Registration number: NTR 4821 (www.trialregister.nl).
- 4 October 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (12) , 1269-1273
Rate and Characteristics of Incompletely Excised Cutaneous Squamous Cell Carcinoma: A Dermatological Daily Practice Multicenter Prospective Cohort Study
BACKGROUND: Incomplete excision of squamous cell carcinoma (cSCC) is associated with an increased risk of recurrence, metastasis, and mortality. OBJECTIVE: To determine the rate and characteristics of incompletely excised cSCC in a dermatological daily practice setting. METHODS: Prospective study of all patients who gave informed consent, with a cSCC treated with standard excision (SE) at 1 of 6 Departments of Dermatology in the Netherlands between 2015 and 2017. Pathological reports were screened to detect all incompletely excised cSCCs. RESULTS: A total of 592 patients with 679 cSCCs were included, whereby most cases were low risk cSCC (89%). The rate of incompletely excised cSCC was 4% (n = 26), and the majority were high-risk cSCCs of which 24 invaded the deep excision margin. CONCLUSION: This prospective study showed that in a dermatological setting, the risk of an incompletely excised cSCC is low (4%) for a cohort that was dominated by low-risk cSCCs. Most incompletely excised cSCCs were of high risk, and incompleteness was almost always at the deep margins. These results suggest that for high-risk cSCC, one should pay attention especially to the deep margin when performing SE, and/or microscopic surgery should be considered.
- 4 October 2022
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 48 (12) , 1269-1273
Rate and Characteristics of Incompletely Excised Cutaneous Squamous Cell Carcinoma: A Dermatological Daily Practice Multicenter Prospective Cohort Study
BACKGROUND: Incomplete excision of squamous cell carcinoma (cSCC) is associated with an increased risk of recurrence, metastasis, and mortality. OBJECTIVE: To determine the rate and characteristics of incompletely excised cSCC in a dermatological daily practice setting. METHODS: Prospective study of all patients who gave informed consent, with a cSCC treated with standard excision (SE) at 1 of 6 Departments of Dermatology in the Netherlands between 2015 and 2017. Pathological reports were screened to detect all incompletely excised cSCCs. RESULTS: A total of 592 patients with 679 cSCCs were included, whereby most cases were low risk cSCC (89%). The rate of incompletely excised cSCC was 4% (n = 26), and the majority were high-risk cSCCs of which 24 invaded the deep excision margin. CONCLUSION: This prospective study showed that in a dermatological setting, the risk of an incompletely excised cSCC is low (4%) for a cohort that was dominated by low-risk cSCCs. Most incompletely excised cSCCs were of high risk, and incompleteness was almost always at the deep margins. These results suggest that for high-risk cSCC, one should pay attention especially to the deep margin when performing SE, and/or microscopic surgery should be considered.